Aiming to Realize Our Corporate Philosophy Under the Long-Term Vision of HOPE 100
The Kyorin Group will promote diversified business expansion and development of the consumer healthcare business while retaining the pharmaceutical business at its core, and by 2023 be recognized both within and outside the Group as a company that supports sound and healthy lifestyles.
Overview of HOPE 100 Stage 1
As the first step in achieving the Kyorin Group’s long-term vision, HOPE 100, for realizing its corporate philosophy, we aim to bolster the forward momentum of its businesses by reorganizing them and building a framework for promoting each business at the HOPE 100 Stage 1.
In promoting HOPE 100 Stage 1, the Group will maintain its core pharmaceutical business, while diversifying its core businesses through the consumer healthcare business. The expression “diversify” indicates our strong desire to develop each business in the Group as a new core driver of the Group’s growth. Specifically, we have are promoting a multi-core strategy and a new pharmaceutical business model, the Pharma Complex Model.
In addition, evolving into a company which supports healthy lifestyles and contributes to individual health requires that the Kyorin Group itself achieves sound growth. This includes not only financial good health, but also efforts to build a solid management platform to ensure that it remains healthy in terms of corporate governance, compliance, and corporate social responsibility.
The "SOP" Behind HOPE 100 Stage 1
HOPE 100 Stage 1, the Kyorin Group's new medium-term business plan, comprises three elements: Strategy, Organization, and Performance. By working to steadily implement each of these components, we aim to enhance corporate value even further.
The Kyorin Group Product Portfolio
The Kyorin Group is working to build a solid business foundation where our pharmaceutical and consumer healthcare business complement one another. This will help them in addressing the business risks inherent in today's changing market conditions.
New Drugs Group
Primary products classified as “New Drugs Group” under the PC Model include the bronchial asthma and allergic rhinitis treatment Kipres, and the overactive bladder (OAB) treatment Uritos.
Under HOPE 100 Stage 1, we are working to expand the market for Kipres and Uritos as far as possible, while in our R&D pipeline, we are focusing on bringing KRP-108 quickly to market and on out-licensing KRP-104. Enhancing the R&D pipeline from a long-term perspective is also a major issue, and we continue to work on enrichment of our R&D pipeline in the franchise customer domain and on early commercialization.
Our plan is to lift sales of “New Drugs Group” from ¥40 billion in fiscal 2010 to ¥50 billion in 2015.
Original Drugs Group
In “Original Drugs Group,” we are using lifecycle management (LCM) to enhance product value and extend product lifecycles. In particular, we are focusing on improving value and extending the lifecycles of key products such as the mucoregulant Mucodyne and Pentasa, a treatment for ulcerative colitis and Crohn’s disease.
Our plan is to lift sales of original drugs from ¥48.0 billion in fiscal 2010 to ¥50 billion in fiscal 2015.
Generic Drugs Group
The Kyorin Group is aiming to expand its business in distinctive generic drugs by working to strengthen collaboration within the Group and aggressively promoting external alliances.
We plan to raise sales from ¥8.9 billion in fiscal 2010, to ¥20.0 billion by fiscal 2015.
